| CRISPR Medicine | This is an overview of articles on delivery
Sign-up to weekly Newsletter here.
Andre Watson, the founder of the gene delivery platform company Ligandal, quickly pivoted his company to develop a therapeutic for COVID-19. But he...
Lack of efficient delivery vehicles has so far hampered CRISPR-Cas9 editing in non-liver tumours. With a new lipid nanoparticle delivery system,...
California-based gene-editing company Scribe Therapeutics recently unveiled its plans to develop the most advanced platform for breakthrough...
All gene therapies have their own advantages and limitations, but one shared feature is the challenge in delivering the gene-editing or replacement...
For CRISPR genome editing, it is important to consider what form the agent is delivered. In this explainer, we look at the different forms (plasmid...
Using 'dead' dCas9 fused to transcriptional activators researchers wake silent genes to alleviate blindness in a mouse model of retinitis pigmentosa -...
Researchers at UC Berkeley have discovered CasΦ, a small and highly compact CRISPR system in bacteriophages. The new CasΦ works in human cells and...
The first clinical trial results indicate that CRISPR is a safe and beneficial gene editing tool in humans. However, full therapeutic translation of...